Tradestie Institutional Equity Comparison Engine

BIIB vs IOVA โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

BIIB Overall Edge

BIIB Captures Institutional Edge (3โ€“1 Pillars ยท 8โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biogen Inc. Common Stock (BIIB) driven by superior Valuation, Growth & Margin, Options & Structure while IOVA counters with relative strength in Momentum & Technical. Fundamentally, BIIB trades at 15.6x Forward P/E with 23.5% operating margin (+10.6% YoY revenue) versus IOVA at N/M Forward P/E and -60.8% operating margin (+80.1% YoY). In options structure, BIIB sits in CONSOLIDATION (6th %ile IV; Dealer Gamma Walls on Pro) against IOVA sits in BREAKDOWN (25th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner BIIB
BIIB 15.6x vs IOVA N/M Fwd P/E
Growth & Margin Winner BIIB
Op Margin 23.5% vs -60.8% ยท YoY +10.6% vs +80.1%
Momentum & Technical Winner IOVA
1Y +53.4% vs +216.5% ยท 52W Pos 92% vs 42%
Options & Structure Winner BIIB
CONSOLIDATION (6th %ile IV) vs BREAKDOWN (25th %ile IV)
BIIB NASDAQ
Biogen Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$252.72
-0.27% 1D
Market Cap $37.0B
1M Return +8.63%
1Y Return +53.41%
Forward P/E 15.6x
Unified AI Score
50.2 / 100 HOLD
Tech 45.0 Fund 52.0 Flow 64.0 Mom 50.0
IOVA NASDAQ
Iovance Biotherapeutics, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$7.63
-1.71% 1D
Market Cap $3.5B
1M Return -44.0%
1Y Return +216.47%
Forward P/E N/M
Unified AI Score
70.4 / 100 BUY
Tech 80.0 Fund 70.0 Flow 70.0 Mom 70.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BIIB +53.41% IOVA +216.47% Spread: +163.06 pp (IOVA Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BIIB Revenue IOVA Revenue BIIB Op. Margin IOVA Op. Margin Margin Edge
FY2018 $13.4B N/A 43.8% N/A BIIB
FY2019 $14.4B N/A 49.0% N/A BIIB
FY2020 $13.4B N/A 33.8% N/A BIIB
FY2021 $11.0B N/A 25.9% N/A BIIB
FY2022 $10.2B N/A 29.9% N/A BIIB
FY2023 $9.84B $0M 11.8% -38735.0% BIIB
FY2024 $9.68B $160M 16.9% -240.9% BIIB
FY2025 $9.89B $260M 13.1% -153.1% BIIB

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BIIB (8) vs IOVA (2)
Institutional Metric BIIB IOVA Criterion Row Winner
Market Capitalization Scale $37.0B $3.5B Larger Scale BIIB
Trailing P/E Ratio Valuation 109.9x N/M Lower Multiple BIIB
Forward P/E Ratio Valuation 15.6x N/M Lower Multiple BIIB
Revenue Growth (YoY) Growth +10.6% +80.1% Higher Growth IOVA
Operating Margin (TTM) Profitability 23.5% -60.8% Higher Margin BIIB
Net Profit Margin Profitability 3.4% -58.2% Higher Margin BIIB
Return on Equity (ROE) Capital Efficiency 1.9% -29.1% Higher ROE BIIB
52-Week Range Position Momentum 92% ($160โ€“$261) 42% ($2โ€“$15) Stronger Trend BIIB
Beta / 30D Volatility Risk Regime 0.27ฮฒ ยท 36% Vol 1.58ฮฒ ยท 144% Vol Lower Realized Risk BIIB
Unified Institutional Score Composite Signal 50.2 / 100 (HOLD) 70.4 / 100 (BUY) Higher Composite IOVA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BIIB vs IOVA Buy Guide
BIIB CONSOLIDATION
17d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 6th %ile
IV Regime Compressed (<25th %ile)
Live BIIB Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
IOVA BREAKDOWN
33d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 25th %ile
IV Regime Compressed (<25th %ile)
Live IOVA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BIIB nor IOVA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.